ATOS
Price
$5.30
Change
+$0.01 (+0.19%)
Updated
Feb 5, 02:23 PM (EDT)
Capitalization
45.38M
55 days until earnings call
Intraday BUY SELL Signals
ERAS
Price
$11.24
Change
+$0.65 (+6.14%)
Updated
Feb 4 closing price
Capitalization
3.48B
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATOS vs ERAS

Header iconATOS vs ERAS Comparison
Open Charts ATOS vs ERASBanner chart's image
Atossa Therapeutics
Price$5.30
Change+$0.01 (+0.19%)
Volume$600
Capitalization45.38M
Erasca
Price$11.24
Change+$0.65 (+6.14%)
Volume$4.11M
Capitalization3.48B
ATOS vs ERAS Comparison Chart in %
ATOS
Daily Signal:
Gain/Loss:
ERAS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATOS vs. ERAS commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Buy and ERAS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ATOS: $5.29 vs. ERAS: $11.24)
Brand notoriety: ATOS and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 198% vs. ERAS: 69%
Market capitalization -- ATOS: $45.38M vs. ERAS: $3.48B
ATOS [@Biotechnology] is valued at $45.38M. ERAS’s [@Biotechnology] market capitalization is $3.48B. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than ATOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 4 TA indicator(s) are bullish while ERAS’s TA Score has 3 bullish TA indicator(s).

  • ATOS’s TA Score: 4 bullish, 4 bearish.
  • ERAS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ATOS is a better buy in the short-term than ERAS.

Price Growth

ATOS (@Biotechnology) experienced а -42.79% price change this week, while ERAS (@Biotechnology) price change was +10.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.81%. For the same industry, the average monthly price growth was +0.47%, and the average quarterly price growth was +32.90%.

Reported Earning Dates

ATOS is expected to report earnings on Apr 01, 2026.

ERAS is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Biotechnology (-3.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($3.48B) has a higher market cap than ATOS($45.4M). ERAS YTD gains are higher at: 202.151 vs. ATOS (-40.226). ATOS has higher annual earnings (EBITDA): -32.84M vs. ERAS (-131.32M). ATOS has less debt than ERAS: ATOS (0) vs ERAS (48.3M). ATOS (0) and ERAS (0) have equivalent revenues.
ATOSERASATOS / ERAS
Capitalization45.4M3.48B1%
EBITDA-32.84M-131.32M25%
Gain YTD-40.226202.151-20%
P/E RatioN/AN/A-
Revenue00-
Total CashN/A288M-
Total Debt048.3M-
FUNDAMENTALS RATINGS
ATOS: Fundamental Ratings
ATOS
OUTLOOK RATING
1..100
57
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
96
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ATOSERAS
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 15 days ago
80%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 11 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ATOS
Daily Signal:
Gain/Loss:
ERAS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IXQUF12.49N/A
N/A
IX Acquisition Corp.
GRNWF0.16N/A
N/A
Greenlane Renewables Inc.
EXALF117.00N/A
N/A
EXAIL TECHNOLOGIES
TSKFF1.39-0.04
-2.87%
Talisker Resources Ltd.
HNSDF91.90-4.14
-4.31%
HENSOLDT AG

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been closely correlated with ACET. These tickers have moved in lockstep 89% of the time. This A.I.-generated data suggests there is a high statistical probability that if ATOS jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-4.34%
ACET - ATOS
89%
Closely correlated
-3.51%
PMN - ATOS
87%
Closely correlated
-1.57%
PHGE - ATOS
86%
Closely correlated
-7.36%
GLSI - ATOS
86%
Closely correlated
-3.62%
ERAS - ATOS
85%
Closely correlated
+6.19%
More